Browse
Submit Data
Databases
API
Help

Dataset Information

13 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

FOLFOXIRI plus Panitumumab or FOLFOX plus Panitumumab in the treatment of metastatic colorectal cancer.

ABSTRACT: Primary objectives: compare the activity of panitumumab in combination with mFOLFOX6 or with mFOLFOXIRI in RAS and BRAF wt mCRC patients in terms of Overall Response Rate according to RECIST version 1.1 Primary endpoints: Distribution of overall response rate (ORR)ORR is defined as the percentage of patients, relative to the total of enrolled subjects, achieving a complete (CR) or partial (PR) response, according to RECIST 1.1 criteria, during the induction and the maintenance phases of treatment. The determination of clinical response will be based on investigator reported measurements. Responses will be evaluated every 8 weeks.

DISEASE(S): Metastatic Colorectal Cancer,Carcinoma Colorettale Metastatico

PROVIDER: 2536351 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Differential T-cell and monocyte responses in hepatocellular carcinoma treated with regorafenib plus nivolumab: an integrated clinical and biomarker analysis of the phase 2 RENOBATE trial

Project description:Regorafenib has anti-tumor activity in patients with unresectable hepatocellular carcinoma (uHCC) with potential immunomodulatory effects, suggesting that its combination with immune checkpoint inhibitor may have clinically meaningful benefits in patients with uHCC. The multicenter, single-arm, phase 2 RENOBATE trial tested regorafenib-nivolumab as front-line treatment for uHCC. Forty-two patients received nivolumab 480 mg every 4 weeks and regorafenib 80 mg daily (3-weeks-on/1-week-off schedule). The primary endpoint was the investigator-assessed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The secondary endpoints included safety, progression-free survival (PFS) and overall survival (OS). ORR per RECIST version 1.1 was 31.0%, meeting the primary endpoint. The most common adverse events were palmar-plantar erythrodysesthesia syndrome (38.1%), alopecia (26.2%) and skin rash (23.8%). Median PFS was 7.38 months. The 1-year OS rate was 80.5%, and the median OS was not reached. Exploratory single-cell RNA sequencing analyses of peripheral blood mononuclear cells showed that long-term responders exhibited T cell receptor repertoire diversification, enrichment of genes representing immunotherapy responsiveness in MKI67+ proliferating CD8+ T cells and a higher probability of M1-directed monocyte polarization. Our data support further clinical development of the regorafenib-nivolumab combination as front-line treatment for uHCC and provide preliminary insights on immune biomarkers of response. ClinicalTrials.gov identifier: NCT04310709 .

2023-12-31 | GSE243572 | GEO

Randomised study to investigate FOLFOXIRI plus Cetuximab or FOLFOXIRI plus bevacizumab as first-line treatment of BRAF-mutated metastatic colorectal cancer (FIRE 4.5)

Project description:Primary objectives: To compare the objective response rate (ORR) according to RECIST 1.1 of treatment with FOLFOXIRI plus cetuximab versus treatment with FOLFOXIRI plus bevacizumab in BRAF-mutated patients.

| 2535112 | ecrin-mdr-crc

Improving treatment selection in patients with cancer using a personalized screening test

Project description:Primary objectives: Evaluate the efficacy of patient-derived tumor organoids to successfully allocate patients for treatment with specific targeted agents. Primary endpoints: Overall clinical response rate (ORR) according to RECIST 1.1.

| 2533692 | ecrin-mdr-crc

Pembrolizumab for locally advanced, irresectable, non-metastatic dMMR colorectal cancers. The PUMA study.

Project description:Primary objectives: To determine the objective response rate (ORR) according to RECIST 1.1 criteria in order to assess the efficacy of pembrolizumab in patients with locally advanced, irresectable dMMR colorectal cancers Primary endpoints: Efficacy of pembrolizumab will be measured by the objective response rate (ORR) according to RECIST 1.1 criteria. The ORR (%) is defined as the proportion of patients with complete response (CR) or partial response (PR) according to RECIST 1.1 as the best observed response to pembrolizumab treatment. All subjects who were treated with at least one cycle of pembrolizumab and underwent subsequent evaluation of their disease will be considered evaluable for response.

| 2756173 | ecrin-mdr-crc

study to investigate cetuximab plus irinotecan as rechallenge 3rd-line treatment of kras, nras and braf wild-type irinotecan-pretreated metastatic colorectal cancer patients progressing after an initial response to a 1st-line cetuximab-containing therapy and a standard 2nd-line.

Project description:Primary objectives: to evaluate, in terms of Overall Response Rate (ORR), the activity of cetuximab plus irinotecan as rechallenge third line treatment of RAS (K- and N-RAS, codons 12, 13, 59, 61, 117, 146) and BRAF (V600E) wild-type, irinotecan-resistant, mCRC patients progressing after an initial response to a first-line irinotecan- and cetuximab-containing therapy and a second-line with FOLFOXIRI/FOLFOX/XELOX plus bevacizumab. Primary endpoints: The primary endpoint of this study is overall response rate (ORR) ORR is defined as the percentage of patients, relative to the total of enrolled subjects, achieving a complete (CR) or partial (PR) response, according to RECIST 1.1 criteria. The determination of clinical response will be based on investigator-reported measurements. Responses will be evaluated with a chest and abdominal computed tomography (CT) scan every 8 weeks. Patients who do not have an on-study assessment will be included in the analysis as non-responders.

| 2533105 | ecrin-mdr-crc

Study of efficacy and safety of laparoscopic intra -abdominal chemotherapy performed in patients with peritoneal carcinomatosis from colorectal , ovarian, gastric cancer and primary peritoneal tumors.

Project description:Primary objectives: Cohort A: - To evaluate the efficacy of PIPAC according to the Overall Response Rate (ORR) in peritoneal carcinomatosis (CP) from colorectal, ovarian, gastric cancers and primary peritoneal tumors.Cohort B- To determine the maximum tolerated dose of oxaliplatin o cisplatin and doxorubicin by PIPAC- To evaluate safety and tolerability of oxaliplatin o cisplatin and doxorubicin by PIPAC Primary endpoints: Overall Response Rate (ORR) according to RECIST criteria (version 1.1)

| 2534264 | ecrin-mdr-crc

First in human study assessing the safety, immunogenicity and efficacy of the cancer vaccine IN01 as second line of treatment in RAS and BRAF mutated metastatic colorectal cancer patients

Project description:Primary objectives: Phase I:Characterize the safety, tolerability and immunogenicity of IN01 in combination with a small molecule inhibitor to confirm the recommended Phase II treatment dose and schedule Phase II:Further assess the efficacy in the different selected mCRC genotypes based on tumour response, biomarkers and survival. Some biomarker collection and/or analysis may be limited to selected sites and patients Primary endpoints: Phase I:• Proportion of patients achieving an anti-EGF antibody immune response• Dose limiting toxicity rates Phase II:Objective response rate (ORR: complete and partial responses) according to RECIST 1.1

| 2539812 | ecrin-mdr-crc

EMERGE is a trial to investigate whether combining the histone deacetylase inhibitor (HDAC inhibitor) drug 4SC-202 with the immunotherapy drug avelumab is safe and improves outcomes for patients with previously treated gastroesophageal or colorectal cancer

Project description:Primary objectives: This trial is designed to evaluate the safety and efficacy of administering Domatinostat a histone deacetylate lysine-specific demethylase inhibitor plus avelumab, an anti-PD-L1 monoclonal antibody in patients with advanced bowel, stomach or oesophageal adenocarcinoma who have been previously treated with chemotherapy. This trial is in 2 stages: the first stage (Phase IIA, safety run-in) will establish a safe and tolerated dose of Domatinostat in combination with avelumab and the second stage (Phase IIB, efficacy) will assess the efficacy of this combination therapy in achieving radiological response according to RECIST 1.1 criteria. Primary Objective is to assess the efficacy of the addition of Domatinostat to avelumab therapy in patients with previously treated advanced OGA and CRC. Outcome measures: ORR according to RECIST 1.1 measured using CT imaging. Timepoint(s) of evaluation of this outcome measure is best response at 6 months.

| 2536948 | ecrin-mdr-crc

Capecitabine Plus Aflibercept as Maintenance Therapy Following Capecitabine Plus Oxaliplatin Plus Aflibercept in Patients With Metastatic Colorectal Cancer

Project description:Primary Objective: Efficacy: To assess the progression-free survival rate at 10 months in patients on maintenance therapy with capecitabine plus aflibercept. Secondary Objectives: To evaluate: * Efficacy: Progression Free Survival (PFS) * Efficacy: Overall Survival (OS) * Efficacy: Objective Response Rate (ORR) as per Response Evaluation Criteria In Solid Tumors (RECIST version 1.1) criteria * Health related Quality of Life (HRQL): EORTC QLQ-C30 scores and EQ5D-3L * Safety Exploratory Objective: To collect blood and tumor samples to perform investigations for potential biomarker testing.

| 2162511 | ecrin-mdr-crc

CAPRI 2 GOIM study: investigate the efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wt tumors at start of first line.

Project description:Primary objectives: Response Rate (RR) per each line of therapy: assessed according to RECIST criteria 1.1 Primary endpoints: Response Rate (RR) per each line of therapy assessed according to RECIST criteria 1.1

| 2540493 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data